MedTrace Logo

Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis

NCT00512096 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-08-01

Study results available
· View outcomes & findings →

Summary

Primary Objective:

-To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.

Conditions

  • Penile Cancer

Interventions

DRUG

Ifosfamide

1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3

DRUG

Paclitaxel (Taxol)

175 mg/m\^2 By Vein Over 3 Hours on Day 1

DRUG

Cisplatin

25 mg/m\^2 By Vein Over 2 Hours on Days 1-3

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Lance Pagliaro, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-08-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512096 on ClinicalTrials.gov